Insulin glargine and lixisenatide Subcutaneous and LarkaDrin Capsules
Determining the interaction of Insulin glargine and lixisenatide Subcutaneous and LarkaDrin Capsules and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
Generic Name: acetaminophen / dichloralphenazone / isometheptene mucate
Brand name: Nodolor
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin glargine and lixisenatide Subcutaneous-Laronidase
- Insulin glargine and lixisenatide Subcutaneous-Laronidase Intravenous
- Insulin glargine and lixisenatide Subcutaneous-Larotrectinib
- Insulin glargine and lixisenatide Subcutaneous-Larotrectinib Capsules
- Insulin glargine and lixisenatide Subcutaneous-Larotrectinib Oral Solution
- Insulin glargine and lixisenatide Subcutaneous-Larotrectinib Sulfate
- LarkaDrin Capsules-Insulin glargine, recombinant Subcutaneous
- LarkaDrin Capsules-Insulin glulisine
- LarkaDrin Capsules-Insulin Glulisine (Cartridges and Pens)
- LarkaDrin Capsules-Insulin Glulisine (Vials)
- LarkaDrin Capsules-Insulin glulisine Subcutaneous
- LarkaDrin Capsules-Insulin human inhaled Inhalation